Cytek Biosciences to Report First Quarter 2024 Financial Results on May 8, 2024
April 29 2024 - 9:00AM
Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis
solutions company, today announced it will report financial results
for the first quarter 2024 after market close on Wednesday, May
8th, 2024. The company’s management will webcast a corresponding
conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m.
Eastern Time to discuss its results, business developments and
outlook.
Live audio of the webcast will be available on the
“Investors” section of the company website at
investors.cytekbio.com.
About Cytek Biosciences, Inc.
Cytek Biosciences (Nasdaq: CTKB) is a leading cell
analysis solutions company advancing the next generation of cell
analysis tools by delivering high-resolution, high-content and
high-sensitivity cell analysis utilizing its patented Full Spectrum
Profiling™ (FSP™) technology. Cytek’s novel approach harnesses the
power of information within the entire spectrum of a fluorescent
signal to achieve a higher level of multiplexing with precision and
sensitivity. Cytek’s FSP platform includes its core instruments,
the Cytek Aurora™ and Northern Lights™ systems; its cell sorter,
the Cytek Aurora™ CS; the Cytek Orion™ reagent cocktail preparation
system; the flow cytometer and imaging products under the
Amnis® and Guava® brands; and reagents, software and
services to provide a comprehensive and integrated suite of
solutions for its customers. Cytek is headquartered in Fremont,
California with offices and distribution channels across the globe.
More information about the company and its products is available at
www.cytekbio.com.
Cytek’s products are for research use only and not
for use in diagnostic procedures (other than Cytek’s Northern
Lights-CLC system and certain reagents, which are available for
clinical use in China and the European Union).
Cytek, Full Spectrum Profiling, FSP, Cytek Aurora,
Northern Lights, Cytek Orion, Amnis and Guava are trademarks of
Cytek Biosciences, Inc.
In addition to filings with the Securities and
Exchange Commission (SEC), press releases, public conference calls
and webcasts, Cytek uses its website
(www.cytekbio.com), LinkedIn page and X (formerly
Twitter) account as channels of distribution of information about
its company, products, planned financial and other announcements,
attendance at upcoming investor and industry conferences and other
matters. Such information may be deemed material information and
Cytek may use these channels to comply with its disclosure
obligations under Regulation FD. Therefore, investors should
monitor Cytek’s website, LinkedIn page, and X account in addition
to following its SEC filings, news releases, public conference
calls and webcasts.
Media Contact:Stephanie OlsenLages
& Associates(949) 453-8080stephanie@lages.com
Investor Contact:Paul GoodsonHead
of Investor Relationspgoodson@cytekbio.com
Cytek Biosciences (NASDAQ:CTKB)
Historical Stock Chart
From Sep 2024 to Oct 2024
Cytek Biosciences (NASDAQ:CTKB)
Historical Stock Chart
From Oct 2023 to Oct 2024